Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Inhibrx is a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms. Following a separation and distribution in May 2024, the company operates as a stand-alone entity focused on two primary clinical programs: ozekibart (INBRX-109), a tetravalent DR5 agonist for oncology, and INBRX-106, a hexavalent OX40 agonist for oncology.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $1,300 | $100 | $1,300 | $100 |
| Net Loss | $(28,654) | $1,858,011 (Income) | $(71,965) | $1,779,301 (Income) |
| Operating Expenses | $28,689 | $160,998 | $71,590 | $234,823 |
| Cash and Cash Equivalents | $186,567 | $226,860 | $186,567 | $226,860 |
| Long-Term Debt (Net) | $99,279 | $0 | $99,279 | $0 |
| Accumulated Deficit | $(178,097) | $(14,403) | $(178,097) | $(14,403) |
Liquidity: As of June 30, 2025, the company held $186.6 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least 12 months from the filing date.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased to $1.3 million in Q2 2025 from $0.1 million in Q2 2024. This was driven by a $1.3 million non-refundable payment from Scithera, Inc., following the achievement of a funding event under a new license agreement.
- Expense Reduction: Operating expenses decreased significantly year-over-year. Q2 2025 expenses were $28.7 million compared to $161.0 million in Q2 2024. This reduction is primarily due to the absence of one-time merger-related costs ($67.5 million in G&A) and accelerated stock-based compensation ($41.1 million in R&D and G&A) recognized in Q2 2024 upon the completion of the separation from the Former Parent.
- Debt Financing: In January 2025, the company entered into a new $100 million loan agreement with Oxford Finance LLC. This replaced the previous debt structure which was extinguished and assumed by the Acquirer (Sanofi subsidiary) during the 2024 separation. The new debt carries an effective interest rate of 12.9%.
- Net Income vs. Loss: The prior year period (Q2 2024) reported a net income of $1.86 billion, which was non-recurring and driven by a $2.0 billion gain related to the transaction with the Acquirer. The current period reflects a normalized net loss of $28.7 million.
Outlook, Risks, and Management Commentary
- Clinical Pipeline Updates:
- ozekibart (INBRX-109): The registration-enabling Phase 2 trial in chondrosarcoma completed full enrollment in July 2025. Data is expected in late October 2025. Interim data for Ewing sarcoma and colorectal cancer cohorts are also expected in late October 2025.
- INBRX-106: A seamless Phase 2/3 trial in head and neck squamous cell carcinoma (HNSCC) is ongoing. Initial Phase 2 data is expected in Q4 2025. If positive, this will ungate the Phase 3 portion.
- Capital Requirements: The company expects to continue incurring significant operating losses. Future funding will likely be required through equity offerings, debt financings, or strategic collaborations. Failure to secure adequate funding could force reductions in spending or delays in development programs.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to raise additional capital, reliance on third-party manufacturers (CDMOs) and research organizations (CROs), and the potential for dilution to existing shareholders in future financing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $186.6 million cash balance against the projected burn rate, considering the new $100 million debt service obligations starting in 2028.
- Clinical Data Readouts: Monitor the anticipated late October 2025 data release for ozekibart (INBRX-109) in chondrosarcoma, Ewing sarcoma, and colorectal cancer, as these are critical value drivers.
- Debt Covenants: Review the terms of the 2025 Loan Agreement, specifically the interest-only period ending February 2028 and the 9% final payment fee, to assess future liquidity constraints.
- Revenue Sustainability: Assess the likelihood of future milestone payments from the Scithera and Regeneron agreements, noting that current revenue is primarily from upfront/license fees rather than product sales.
- INBRX-106 Phase 2/3 Progress: Track enrollment and initial data for the HNSCC trial in Q4 2025, which determines the progression to Phase 3.